Article
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 1 Feb 2020
D'Ambrosio Roberta, Pasulo Luisa, Giorgini Alessia, Spinetti Angiola, Messina Emanuela, Fanetti Ilaria, Puoti Massimo, Aghemo Alessio, Viganò Paolo, Vinci Maria, Menzaghi Barbara, Lombardi Andrea, Pan Angelo, Pigozzi Marie Graciella, Grossi Paolo, Lazzaroni Sergio, Spinelli Ombretta, Invernizzi Pietro, Maggiolo Franco, Terreni Natalia, Monforte Antonella D'Arminio, Poggio Paolo Del, Taddei Maria Teresa, Colombo Silvia, Pozzoni Pietro, Molteni Chiara, Brocchieri Alessandra, Bhoori Sherrie, Buscarini Elisabetta, Centenaro Riccardo, Mendeni Monia, Colombo Alberto Eraldo, Di Marco Mariella, Dionigi Elena, Bella Daniele, Borghi Marta, Zuin Massimo, Zaltron Serena, Noventa Franco, Annalisa De Silvestri, Lampertico Pietro, Fagiuoli Stefano
Abstract excerpt
BACKGROUND: Sofosbuvir (SOF)-based regimens have been associated with renal function worsening in HCV patients with estimated glomerular filtration rate (eGFR) ≤ 45 ml/min, but further investigations are lacking. AIM: To assess renal safety in a large cohort of DAA-treated HCV patients with any chronic kidney disease (CKD). METHODS: All HCV patients treated with DAA in Lombardy (December 2014-November 2017) with...
Read the complete abstract on PubMed